Imperial X plc is quoted on the NEX Exchange (NEX) in London. The Company seeks acquisition and other development opportunities in the developing market for producing and/or distributing Medicinal Cannabis, derivatives of it and/or related products.
The Directors believe that the market for products which are based on, or contain, cannabis derived cannabinoids is growing strongly due to the increased awareness of the benefits of cannabinoids to various aspects of health and because they are now legal in an increasing number of states in the USA, as well as other countries around the world. Indeed, the UK government has recently legalised prescribed medicinal cannabis for certain indications following a number of high-profile cases involving the use of cannabis products.
The Directors believe that there are numerous investment opportunities within both private and public businesses in the Medicinal Cannabis sector in countries that are internationally recognised as having well-developed and reputable laws and regulations for the research and production of Medicinal Cannabis and that comply with the United Nation’s conventions on narcotics.
Once secured, it is the Company’s intention to quickly grow the value of acquired assets via an injection of development funding and the provision of specialist production and/or marketing expertise.
Imperial X believes that the successful implementation of this strategy will deliver long-term share price growth for its stock holders.